Alcohol use disorder (AUD) impacts millions of people across the world, including at least 17 million US patients [1]. Nearly 100,000 patients die each year because of AUD [1], which induces organ injury throughout the body, including in the liver and in the brain. In both humans and mice, alcohol intoxication leads to central nervous system (CNS) inflammation and neurodegeneration [2–4]. Recent studies using animal models have shown that inflammatory signaling not only contributes to neurodegeneration but also to alcohol addiction [5–7], making targeting of neuroinflammation a critical approach in the treatment of AUD.
